ATE143263T1 - Behandlung von neurodegenerativen erkrankungen - Google Patents

Behandlung von neurodegenerativen erkrankungen

Info

Publication number
ATE143263T1
ATE143263T1 AT93301534T AT93301534T ATE143263T1 AT E143263 T1 ATE143263 T1 AT E143263T1 AT 93301534 T AT93301534 T AT 93301534T AT 93301534 T AT93301534 T AT 93301534T AT E143263 T1 ATE143263 T1 AT E143263T1
Authority
AT
Austria
Prior art keywords
treatment
neurodegenerative diseases
meta
neurodegenerative
diseases
Prior art date
Application number
AT93301534T
Other languages
English (en)
Inventor
William S Caldwell
Patrick M Lippiello
Original Assignee
Reynolds Tobacco Co R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reynolds Tobacco Co R filed Critical Reynolds Tobacco Co R
Application granted granted Critical
Publication of ATE143263T1 publication Critical patent/ATE143263T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
AT93301534T 1992-03-02 1993-03-01 Behandlung von neurodegenerativen erkrankungen ATE143263T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/844,364 US5212188A (en) 1992-03-02 1992-03-02 Method for treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
ATE143263T1 true ATE143263T1 (de) 1996-10-15

Family

ID=25292523

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93301534T ATE143263T1 (de) 1992-03-02 1993-03-01 Behandlung von neurodegenerativen erkrankungen

Country Status (8)

Country Link
US (1) US5212188A (de)
EP (1) EP0559413B1 (de)
JP (1) JPH0624983A (de)
AT (1) ATE143263T1 (de)
DE (1) DE69304955T2 (de)
DK (1) DK0559413T3 (de)
ES (1) ES2093361T3 (de)
GR (1) GR3022072T3 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
US5852041A (en) * 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5616707A (en) * 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
US5824692A (en) * 1995-01-06 1998-10-20 Lippiello; Patrick Michael Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5731314A (en) * 1995-01-06 1998-03-24 Bencherif; Merouane Pharamceutical compositions for prevention and treatment of tourette's syndrome
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
WO1996020600A1 (en) * 1995-01-06 1996-07-11 R.J. Reynolds Tobacco Company Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US6194581B1 (en) 1995-04-07 2001-02-27 Merck & Co., Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5585388A (en) * 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US20020052497A1 (en) * 2000-03-09 2002-05-02 Targacept, Inc. Compounds capable of activating cholinergic receptors
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US6979695B2 (en) * 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6166048A (en) 1999-04-20 2000-12-26 Targacept, Inc. Pharmaceutical compositions for inhibition of cytokine production and secretion
DK0900200T5 (da) 1996-04-23 2010-01-11 Targacept Inc Farmaceutiske sammensætninger til forebyggelse og behandling af sygdom i centralnervesystemet
US6531606B1 (en) * 1997-02-21 2003-03-11 Targacept, Inc. Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US5861423A (en) * 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US5811442A (en) * 1997-02-21 1998-09-22 Bencherif; Merouane Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
US7214686B2 (en) * 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
PT1056458E (pt) * 1998-02-24 2005-08-31 Univ Wake Forest Tratamento de dor cronica
WO1999051216A2 (en) * 1998-04-02 1999-10-14 R.J. Reynolds Tobacco Company 3-pyridyloxyalkylamine or aryloxyalkylamine derivatives as cholinergic agonists
US20050131034A1 (en) * 1998-06-16 2005-06-16 Caldwell William S. Compounds capable of activating cholinergic receptors
US6232316B1 (en) 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
US7790757B2 (en) * 1998-06-16 2010-09-07 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6262124B1 (en) 1998-10-22 2001-07-17 Gary Maurice Dull Pharmaceutical compositions and methods for use
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
US6455554B1 (en) 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
EP1185514A1 (de) * 1999-06-07 2002-03-13 Targacept, Inc. Pharmaceutische zusammensetzungen und verwendungsmethode
US6890935B2 (en) * 1999-11-01 2005-05-10 Targacept, Inc. Pharmaceutical compositions and methods for use
FR2810886B1 (fr) * 2000-06-05 2002-12-27 Sanjuan Benito Arranz Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : de la nicotine et du sildenafil (ou des derives des deux)
US6852741B2 (en) 2001-12-31 2005-02-08 University Of Florida Compositions and methods for treatment of neurological disorders
EP1539152A4 (de) * 2002-08-02 2006-10-18 Nutraceutical Dev Corp ENTWICKLUNG DER MUSKELMASSE IN EINEM SûUGETIER
WO2005037832A2 (en) * 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
WO2005096992A1 (en) * 2004-04-02 2005-10-20 Arterial Remodelling Technologies, Inc. Polymer-based stent assembly
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US7780981B2 (en) 2004-09-13 2010-08-24 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
UA88792C2 (ru) 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) * 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
US8017785B2 (en) * 2006-05-09 2011-09-13 Astrazeneca Ab Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
US20080085888A1 (en) * 2006-09-15 2008-04-10 Breining Scott R Therapeutic Combinations
US20100028447A1 (en) * 2007-01-22 2010-02-04 Targacept, Inc. Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs
JP2010523587A (ja) * 2007-04-02 2010-07-15 パーキンソンズ インスティテュート 治療処置の副作用の低減のための方法および組成物
CN101772343A (zh) * 2007-07-31 2010-07-07 塔格赛普有限公司 (2s)-(4e)-n-甲基-5-(3-(5-异丙氧基吡啶)基)-4-戊烯-2-胺的经皮给药
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
SG185497A1 (en) 2010-05-20 2012-12-28 Astrazeneca Ab New process for the preparation of aryl substituted olefinic amines
EP2729148A4 (de) 2011-07-06 2015-04-22 Parkinson S Inst Zusammensetzungen und verfahren zur behandlung von symptomen bei patienten mit morbus parkinson
CA2949395C (en) * 2014-05-16 2024-01-02 Synaptec Development Llc Clearance of amyloid.beta.
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
CA2977814A1 (en) 2015-03-12 2016-09-15 Chrono Therapeutics Inc. Craving input and support system
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
JP7420797B2 (ja) 2018-05-29 2024-01-23 モーニングサイド ベンチャー インベストメンツ リミテッド 薬剤送達の方法及びシステム

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870794A (en) * 1974-02-20 1975-03-11 Foundation For Behavioral Rese Treatment of certain emotional disorders with nicotine compounds
HU179164B (en) * 1979-12-14 1982-08-28 Egyt Gyogyszervegyeszeti Gyar Process for producing cycloalkyl-ethers of alkanolamines
US4442292A (en) * 1981-01-29 1984-04-10 Philip Morris Incorporated Optically active nicotine analogs and process for their preparation
US4578394A (en) * 1984-12-10 1986-03-25 Hoechst-Roussel Pharmaceuticals Incorporated Cholinergic function increasing 3-[N-(pyridyl) carbamoyl]-1,4-dihydropyridines
US4965074A (en) * 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
US4765985A (en) * 1985-03-05 1988-08-23 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4863930A (en) * 1986-12-19 1989-09-05 Adhikary Parimal K Use of substituted 5H-pyrido- and 5H-thiazolo(2',1':2,3)imidazo (4,5-b)indoles as cholinomimetic agents
IL88156A (en) * 1987-11-13 1997-02-18 Novo Nordisk As Azacyclic compounds their preparation and pharmaceutical compositions containing them
IE62662B1 (en) * 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
US5015741A (en) * 1989-10-03 1991-05-14 Philip Morris Incorporated Nicotine analogs

Also Published As

Publication number Publication date
EP0559413B1 (de) 1996-09-25
DK0559413T3 (de) 1997-03-10
GR3022072T3 (en) 1997-03-31
US5212188A (en) 1993-05-18
DE69304955T2 (de) 1997-04-10
JPH0624983A (ja) 1994-02-01
ES2093361T3 (es) 1996-12-16
EP0559413A1 (de) 1993-09-08
DE69304955D1 (de) 1996-10-31

Similar Documents

Publication Publication Date Title
ATE143263T1 (de) Behandlung von neurodegenerativen erkrankungen
ATE169219T1 (de) Behandlung von katarakt mit 15-keto- prostaglandinderivaten
ATE137116T1 (de) Behandlung von entzündlichen erkrankungen mit 15- ketoprostaglandinen
DE69300321T2 (de) Behandlung neurodegenerativer Erkrankungen.
NO973581D0 (no) Fremgangsmåte for fremstilling av mono-N-substituerte tetraazamakrosykliske forbindelser
DE69024744T2 (de) Behandlung der hepatobilären Erkrankung mit 15-Ketoprostaglandin-Derivaten
DE69419954D1 (de) Arzneimittel zur Behandlung von Hauterkrankungen
ATE162717T1 (de) Behandlung kardialer dysfunktion mit 15- ketoprostaglandinderivaten
DE69212119T2 (de) Behandlung von Fotoresistabfall
NO942756D0 (no) Behandling av glaucoma
ATE146964T1 (de) Behandlung von katarakt mit prostacyclinverbindungen
DE69124415D1 (de) Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen
DE69306831T2 (de) Behandlung von Flüssigkeiten
LV10391A (lv) Alkilfosforskabes savienojumu izmantosana psoriazes tipa slimibu arstesanai
DE69318644D1 (de) Behandlung von Flüssigkeiten
DE69404370T2 (de) Gelatinase A zur Behandlung von der Alzheimerschen Krankheit
NO862454D0 (no) Fremgangsmaate for behandling av peroxydblekeavluter.
ATE102036T1 (de) Behandlung von hyperlipidemia mit 15-ketoprostaglandin-verbindungen.
ATE86857T1 (de) Transdermate magensafthemmende wirkstoffe zur behandlung von magen-darm-erkrankungen.
NO921003L (no) Forbindelser for behandling av leukotrien-relaterte sykdommer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee